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Optimization of human 
mesenchymal stem cell 
manufacturing: the effects of 
animal/xeno-free media
Angelos Oikonomopoulos1, Welmoed K. van Deen1,2, Aida-Rae Manansala3, 
Precious N. Lacey1, Tamera A. Tomakili1, Alyssa Ziman3 & Daniel W. Hommes1
Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been evaluated 
for the treatment of immunological diseases. However, the animal-derived growth supplements 
utilized for MSC manufacturing may lead to clinical complications. Characterization of alternative 
media formulations is imperative for MSC therapeutic application. Human BMMSC and AdMSC were 
expanded in media supplemented with either human platelet lysates (HPL), serum-free media/
xeno-free FDA-approved culture medium (SFM/XF), or fetal bovine serum (FBS) and the effects on 
their properties were investigated. The immunophenotype of resting and IFN-γ primed BMMSC and 
AdMSC remained unaltered in all media. Both HPL and SFM/XF increased the proliferation of BMMSC 
and AdMSC. Expansion of BMMSC and AdMSC in HPL increased their differentiation, compared to 
SFM/XF and FBS. Resting BMMSC and AdMSC, expanded in FBS or SFM/XF, demonstrated potent 
immunosuppressive properties in both non-primed and IFN-γ primed conditions, whereas HPL-
expanded MSC exhibited diminished immunosuppressive properties. Finally, IFN-γ primed BMMSC 
and AdMSC expanded in SFM/XF and HPL expressed attenuated levels of IDO-1 compared to FBS. 
Herein, we provide strong evidence supporting the use of the FDA-approved SFM/XF medium, in 
contrast to the HPL medium, for the expansion of MSC towards therapeutic applications.
Stem cell therapy utilizing mesenchymal stem cells (MSC) has emerged as an alternative approach in 
various pathologic conditions. MSC have been applied toward the treatment of bone diseases, cartilage 
repair, myocardial infarction, and auto-immune diseases such as graft versus host disease (GVHD) and 
inflammatory bowel disease (IBD)1–8. MSC are self-renewing and multipotent adult stem cells. They 
are typically obtained from the bone marrow, but can also be isolated from other tissues such as sub-
cutaneous fat, skeletal muscle, amniotic fluid, and placenta among others. More recently, MSC were 
shown to possess potent immunomodulatory properties and the ability to alter the function of immune 
cells9–13. The immunosuppressive properties of MSC can be augmented by pre-stimulation (priming) 
with pro-inflammatory cytokines such as interferon-γ (IFN-γ )14–17. Recent data from our laboratory 
have confirmed the immunomodulatory efficacy of IFN-γ primed bone marrow derived MSC (BMMSC) 
compared to non-primed BMMSC in experimental models of colitis in mice14.
Salutary application of MSC requires their ex vivo expansion in order to reach appropriate cell num-
bers to achieve therapeutic outcomes. Thus, identification of optimal culture conditions is a prerequisite 
for MSC clinical applications. Animal derived growth supplements, such as fetal bovine serum (FBS), 
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have been predominantly used for MSC expansion in clinical protocols. However, utilization of animal 
derived products bears critical limitations and safety concerns18, such as animal derived (xeno) antigens 
and infectious agents present in FBS that might be transmitted to the recipient of MSC therapy19–25. 
Moreover, the precise composition of FBS remains unclear and often there are significant variations 
between lots26. To avoid undesirable complications, alternative animal product-free media formulations 
have been evaluated. Recent efforts have focused on the development of animal serum-free culture media 
with the utilization of human derived growth supplements for MSC expansion, such as human platelet 
lysates (HPL)27–41. Additionally, chemically-predefined animal and human serum-free culture media have 
been developed for the expansion of MSC towards clinical applications42–46. Recently, the Federal Drug 
Administration (FDA) approved the first commercially available pre-defined xeno-free culture medium 
specially formulated for the expansion of human MSC47.
In order to determine if animal-free/xeno-free media can be used for optimal MSC expansion, we 
analyzed the functional properties of non-primed and IFN-γ primed BMMSC and adipose derived MSC 
(AdMSC) expanded in xeno-free media formulations. We found that the pre-defined serum-free media/
xeno-free culture medium (SFM/XF) in contrast to HPL-supplemented medium represents an alternative 
way to expand BMMSC and AdMSC that preserves their functional properties.
Results
Effects of alternative culture conditions on the morphology of rested and primed BMMSC and 
AdMSC. Resting (vehicle-treated, non-primed) BMMSC cultured in 10%HPL (BMMSC-10%HPL) 
exhibited an increase in length and decrease in size (area) compared to SFM/XF and FBS treated 
BMMSC (BMMSC-SFM/XF (p < 0.0001) and BMMSC-10%FBS (p < 0.0014), respectively) (Fig.  1A 
and Supplementary Figures 1E, C, and A, respectively). No difference in size and shape was observed 
between BMMSC-SFM/XF and BMMSC-10%FBS under resting conditions (Fig. 1A and Supplementary 
Figures 1C and A). Similarly, AdMSC-SFM/XF and AdMSC-10%HPL appeared smaller (p < 0.0001) in 
size compared to AdMSC-10%FBS (Fig. 1B and Supplementary Figures 2C, E, and A, respectively, and 
Supplementary Tables 1 and 2).
IFN-γ priming increased the cell size (p < 0.0001) and changed the morphology of BMMSC to a less 
elongated shape in 10%FBS but not in SFM/XF or 10%HPL, compared to the respective resting cells 
(Fig. 1A and Supplementary Figures 1B, D, and F). Similarly, IFN-γ priming increased (p < 0.0001) the 
cell size and changed the morphology of AdMSC to a less elongated shape in 10%FBS and SFM/XF but 
not in 10%HPL (Fig. 1B and Supplementary Figures 2B, D, and F, and Supplementary Tables 1 and 2). 
The above results show that alternative culture conditions in combination with IFN-γ priming lead to 
morphological changes in BMMSC and AdMSC. These changes in size and morphology could indicate 
Figure 1. Cell size quantification of resting and IFN-γ primed BMMSC expanded in alternative media 
formulations. Diagram shows quantitative analysis of (A) BMMSC and (B) AdMSC surface area in all 
media formulations 3 days post priming. Data are mean values ± standard error of the mean (s.e.m.).
www.nature.com/scientificreports/
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changes in cell proliferation and/or differentiation; therefore we examined the effects of alternative media 
formulations on MSC homeostasis.
Effects of alternative media formulations on the immunophenotypic profile of BMMSC and 
AdMSC. To monitor the identity and the phenotype of BMMSC and AdMSC in alternative media for-
mulations, we examined the expression of six well established cell surface markers (CD34, CD45, CD14, 
CD90, CD105, and CD73) as well as HLA-DR48. BMMSC and AdMSC were negative for the expression 
of the hematopoietic markers CD14, CD34, and CD45 in all media formulations and positive for the 
expression of CD90, CD105, and CD73 (Fig. 2A,B). The immunophenotypic profile of both BMMSC and 
AdMSC was not altered by IFN-γ priming (Fig. 2A,B and Supplementary Tables 1 and 2). Interestingly, 
in AdMSC-SFM/XF the expression level of CD105 was reduced following IFN-γ priming (Fig. 2B).
We and others have previously shown that HLA-DR is not expressed in resting BMMSC and AdMSC, 
and it is highly up-regulated following IFN-γ priming14. Indeed, resting BMMSC expressed only mar-
ginal levels of HLA-DR in all media formulations (Supplementary Figures 3A,C,E,G), while IFN-γ 
priming resulted in significant up-regulation (p < 0.0001) of HLA-DR in BMMSC-10%FBS, and to a 
lesser extent, in BMMSC-SFM/XF and BMMSC-10%HPL (p < 0.001) (Supplementary Fig. 3B,D,F,G, 
and Supplementary Table 1 and Table 2). HLA-DR was highly expressed (p < 0.0001) in AdMSC fol-
lowing IFN-γ priming in all media formulations (Supplementary Figures 4B,D,F,G), compared to 
HLA-DR-negative resting AdMSC (Supplementary Figures 4A,C,E,G, and Supplementary Tables 1 and 
2). The above data shows that alternative culture conditions marginally affect the induction of HLA-DR 
and potentially the priming efficiency of BMMSC and AdMSC.
Effects of alternative media formulations on the differentiation capacity of BMMSC and 
AdMSC. BMMSC and AdMSC retained their adipogenic and osteogenic differentiation capacity in 
all media formulations as evidenced by immunostaining for lipid droplets (oil Red staining) and alka-
line phosphatase (ALP) respectively (Supplementary Fig. 5 and 6). To quantify the extent of adipogenic 
differentiation in BMMSC and AdMSC we measured the expression levels of adiponectin, and PPAR-γ 
in both MSC types expanded in all media formulations. Culture in 10%HPL supplemented medium 
demonstrated the highest levels of adiponectin and PPAR-γ compared to 10%FBS and SFM/XF for both 
BMMSC (p < 0.0001) and AdMSC (p < 0.04 and p < 0.003, respectively) (Supplementary Figure 7A, B 
and C, D respectively, and Supplementary Tables 1 and 2).
Next we measured the expression levels of ALP a marker of osteogenic differentiation. BMMSC-
10%HPL expressed the highest (p < 0.001) levels of ALP, followed by BMMSC-SFM/XF and BMMSC-
10%FBS (Supplementary Figure 8A). Likewise, AdMSC-10%HPL expressed the highest levels of ALP, 
followed by AdMSC-10%FBS (p < 0.05) and AdMSC-SFM/XF (p < 0.01) (Supplementary Figure 8B, and 
Figure 2. Alternative media formulations do not alter the immunophenotypic profile of resting (non-
primed) and IFN-γ primed BMMSC and AdMSC. Diagrams demonstrate the fraction of BMMSC (A) and 
AdMSC (B) expressing CD34, CD14, CD45, CD90, CD105 and CD73 cell surface markers in all culture 
conditions. All data points are generated by performing at least two independent experiments in triplicates. 
Data are mean values ± s.e.m.
www.nature.com/scientificreports/
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Supplementary Tables 1 and 2). The above data suggest that although the alternative culture condi-
tions have minimal effects on the immunophenotypic profile of BMMSC and AdMSC, they significantly 
impact their differentiation potential.
Alternative media formulations augment the proliferation capacity of BMMSC and 
AdMSC. Therapeutic application of MSC in inflammatory diseases, such as IBD, requires rapid ex 
vivo expansion of cells in conditions that do not compromise their immunomodulatory properties. 
Thus, we examined the effects of alternative media formulations on BMMSC and AdMSC prolifera-
tion via BrdU incorporation assays in resting and priming conditions. BrdU is a thymidine analog that 
incorporates into the DNA of the cell during the S-phase of the cell cycle. As shown in Fig. 3G (white 
bars), BMMSC-10%HPL followed by BMMSC-SFM/XF (p = 0.0004) exhibited significantly higher BrdU 
incorporation in resting conditions, compared with BMMSC-10%FBS (p = 0.0004). Similarly, AdMSC-
10%HPL demonstrated the highest BrdU levels followed by AdMSC-SFM/XF, in comparison to AdMSC-
10%FBS (p = 0.0004) (Fig.  4G, white bars). Representative images of BrdU flow cytometric analysis of 
BMMSC and AdMSC in all experimental conditions are presented in Figs 3A–F and 4A–F. IFN-γ prim-
ing significantly impaired the proliferation capacity of BMMSC in comparison to resting cells in all 
media formulations (BMMSC-10%FBS p < 0.0001, BMMSC-SFM/XF p = 0.012, and BMMSC-10%HPL 
p < 0.0001) (Fig.  3G, white vs black bars). Interestingly, IFN-γ priming decreased the proliferation 
capacity of AdMSC cultured in 10%FBS (p = 0.0123) and SFM/XF (p = 0.0123) but not in the 10%HPL 
(Fig.  4G, white vs black bars). Overall, the above results provide strong evidence that both alterna-
tive media formulations and particularly HPL-supplemented media can augment the growth potential 
Figure 3. Effects of alternative culture media and IFN-γ priming on the proliferation capacity of 
BMMSC. Representative images of flow cytometric analysis of BrdU incorporation assays in resting and 
primed BMMSC expanded in 10%FBS (A,B), SFM/XF medium (C,D), 10%HPL (E,F). (G) Quantification 
of BrdU incorporation assays in BMMSC cells. All data points are generated by performing at least two 
independent experiments in triplicates. Data are mean values ± s.e.m.
www.nature.com/scientificreports/
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of BMMSC and AdMSC. Additionally, we provide evidence that IFN-γ priming mediates anti-growth 
effects predominantly on BMMSC and to a lesser extent on AdMSC.
Human platelet lysate compromises the immunosuppressive properties of BMMSC and 
AdMSC. We assessed the immunosuppressive properties of BMMSC and AdMSC expanded in 
alternative media formulations in resting and primed conditions through co-culture assays of CFSE 
loaded human peripheral blood mononuclear cells (PBMC) with BMMSC and AdMSC. Resting 
BMMSC-10%FBS and AdMSC-10%FBS suppressed the proliferation of PBMC indicating an increase 
in their immunosuppressive properties. This effect was further enhanced (p < 0.05) by IFN-γ priming 
(Fig. 5A,B and Supplementary Tables 1 and 2). Similarly, resting BMMSC-SFM/XF decreased the pro-
liferation capacity of PBMC (Fig. 5A,B). IFN-γ priming of BMMSC-SFM/XF did not further augment 
their immunosuppressive properties (Fig.  5A,B). On the contrary, BMMSC and AdMSC expanded in 
HPL-supplemented medium had no effect on the proliferation of PBMC in both resting and IFN-γ 
priming conditions (Fig. 5A,B). This result suggests that the immunosuppressive properties of BMMSC 
and AdMSC are inhibited by HPL-supplemented medium. Moreover, the pre-defined SFM/XF culture 
medium could represent an alternative to the FBS-supplemented medium as it maintains the immuno-
suppressive properties of BMMSC.
BMMSC and AdMSC expanded in alternative media formulations show reduced levels of 
IDO-1. Indoleamine 2, 3-dioxygenase 1 (IDO-1) is an established mediator of the immunosuppressive 
Figure 4. Effects of different media formulations and IFN-γ priming on the proliferation capacity 
of AdMSC. Representative images of flow cytometric analysis of BrdU incorporation assays in resting 
and primed AdMSC expanded in 10%FBS (A,B), SFM/XF medium (C,D), and 10%HPL (E,F). (G) 
Quantification of BrdU incorporation assays in AdMSC cells. All data points are generated by performing at 
least two independent experiments in triplicates. Data are mean values ± s.e.m.
www.nature.com/scientificreports/
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properties of human MSC. To examine the levels of IDO-1, we performed protein expression analysis 
in BMMSC and AdMSC expanded in all media formulations. Under resting conditions IDO-1 was not 
detected in BMMSC and AdMSC expanded in all media formulations (Fig. 6A–D, respectively). However, 
following IFN-γ priming IDO-1 was significantly (p < 0.0001) up-regulated (Fig.  6A–D, respectively). 
IFN-γ treated BMMSC-10%FBS expressed the highest levels of IDO-1 followed by BMMSC-SFM/XF 
and BMMSC-10%HPL (p < 0.001) (Fig. 6A,B). Similarly, IFN-γ primed AdMSC-FBS expressed the high-
est levels of IDO-1 followed by AdMSC-10%HPL and AdMSC-SFM/XF (p < 0.001) (Fig. 6C,D). Hence, 
both SFM/XF and HPL-supplemented media increase IDO-1 expression following IFN-γ treatment 
albeit to a lesser extent than 10%FBS.
Analytical tables summarizing all results obtained from non-primed and IFN-γ primed BMMSC and 
AdMSC expanded in all media-formulations are presented in Supplementary Table 1 and Table 2.
Discussion
MSC offer new therapeutic strategies for the treatment of refractory cases of IBD and other inflamma-
tory diseases. Administering therapeutically meaningful numbers of MSC in patients requires extensive 
in vitro cell propagation utilizing FBS as the main source of growth supplement. However, various side 
effects related to the utilization of animal derived products such as FBS for the development of MSC 
have been reported. Thus, there is an unmet need for the identification of novel animal free culture con-
ditions for the expansion of MSC. HPL can be obtained from volunteer blood donors and is available 
in most hospitals and transfusion centers. Since HPL is produced under institutional standard operating 
procedures, and per AABB (American Association of Blood Banks) requirements and U.S. Food and 
Drug Administration (FDA) regulations, it is a safe alternative medium for MSC production. HPL can 
sustain the growth of MSC without affecting their immunophenotype. On the other hand, recent reports 
have indicated that HPL can either maintain or diminish the immunosuppressive properties of MSC27. 
Figure 5. BMMSC and AdMSC expanded in FBS and SFM/XF, but not in HPL, inhibit the proliferation 
of PBMC. CFSE profiling of CD3+/CD28+ pre-stimulated PBMC co-cultured with resting and IFN-γ 
primed BMMSC (A) and AdMSC (B). Diagrams demonstrate the proportion of CFSE+ PBMC in the last 
three cell divisions in every condition. Pre-stimulated PBMC cultured in the absence of BMMSC were used 
as controls (No MSC). All data points are generated by performing at least two independent experiments in 
triplicates. Data are mean values ± s.e.m.
www.nature.com/scientificreports/
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Thus the effects of HPL on the immunosuppressive properties of MSC remain controversial and require 
further investigation.
The serum-free/xeno-free medium (SFM/XF) is a commercially available product that meets good 
manufacturing practice (GMP) standards and was recently approved by the (FDA) for expansion of 
MSC towards therapeutic applications42,45. Still, very little is known about the effects of SFM/XF on the 
immunosuppressive properties of BMMSC and AdMSC. Therefore, the goal of the current study is to 
perform a comprehensive comparison of the functional properties of resting and IFN-γ primed BMMSC 
and AdMSC expanded in alternative culture media formulations (HPL and SFM/XF).
We found that both alternative media formulations (HPL and SFM/XF) significantly enhanced the 
proliferation capacity of MSC as evidenced by the increased BrdU incorporation rate. These results are in 
agreement with previous studies demonstrating that HPL-supplement and SFM/XF can augment the pro-
liferation of BMMSC and AdMSC35,45. Substitution of FBS by HPL or SFM/XF can reduce the required 
amount of MSC manufacturing time and accelerate the production of MSC in therapeutically relevant 
numbers.
Figure 6. IFN-γ priming differentially regulates the expression of IDO-1 in BMMSC and AdMSC 
cultured in alternative media formulations. Western blot analysis of IDO-1 in (A) BMMSC and (C) 
AdMSC expanded in various culture media formulations. Quantification of IDO-1 expression levels in 
(B) BMMSC and (D) AdMSC. All data points are generated by performing at least two independent 
experiments in triplicates. Data are mean values ± s.e.m. * indicate comparison between Vehicle and IFN-γ 
at every condition. 
www.nature.com/scientificreports/
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Additionally, our data shows that IFN-γ priming mediates anti-proliferative effects on both BMMSC 
and AdMSC. However, IFN-γ primed BMMSC and AdMSC demonstrate superior immunosuppressive 
properties and thus represent potential potent candidates for future clinical trials of immunological dis-
orders. Further exploration of their function under serum-free expansion conditions is needed. The 
effects of alternative media formulations on IFN-γ primed MSC have been largely overlooked. This is of 
paramount importance for the design of future MSC clinical trials, as priming with pro-inflammatory 
cytokines dramatically increases their anti-inflammatory properties.
Our data also suggests that expansion of both BMMSC and AdMSC in HPL supplemented media 
abolishes their immunosuppressive properties. BMMSC-10%HPL and AdMSC-10%HPL were unable 
to block the proliferation of CD3+/CD28+ activated T-cells in comparison to BMMSC-10%FBS and 
AdMSC-10%FBS. Priming of both cell types with IFN-γ did not increase their immunosuppressive prop-
erties in contrast to the respective cell types expanded in FBS. In a recent paper by Menard et al. it was 
shown that BMMSC and AdMSC expanded in HPL-supplemented media maintained their immuno-
suppressive properties similarly to BMMSC expanded in FBS49. The observed discrepancies between the 
current manuscript and the one by Menard et al. are most likely attributed to differences in the HPL pro-
duction (apheresis-procedure versus whole blood processing). Previous studies have shown that whole 
blood derived HPL and apheresis derived HPL have similar growth promoting capacities on MSC33. 
Our work suggests that although apheresis derived HPL is a potent growth promoting supplement, it 
abrogated the immunosuppressive properties of MSC. Overall, HPL needs to be carefully evaluated as an 
alternative growth medium for MSC due to the documented discrepancies on the immunosuppressive 
properties of the cells.
SFM/XF represents the first FDA-approved xeno-free culture media for the expansion of BMMSC 
and AdMSC towards clinical applications. SFM/XF is a GMP-compatible serum-free/xeno-free culture 
medium with a trademarked list of components, including but not limited to human albumin, lipo-
proteins, and recombinant human growth factors44. Our data show that SFM/XF not only augments 
the proliferation capacity of BMMSC and AdMSC but preserves their immunosuppressive properties. 
Interestingly, IFN-γ priming of the SFM/XF-expanded BMMSC and AdMSC cells did not further poten-
tiate their immunosuppressive properties.
Our study offers a detailed characterization of MSC expanded in various media formulations that 
can serve as a foundation for the development of cell therapy protocols. Our data provides a strong 
framework for the development of a serum-free/xeno-free GMP-compatible manufacturing practice for 
the expansion of BMMSC and AdMSC.
Methods
MSC expansion. Human donor derived BMMSC and AdMSC were purchased from Lonza (Basel, 
Switzerland). BMMSC and AdMSC were initially expanded in FBS-supplemented Dulbecco’s modified 
Eagle’s-low glucose medium (DMEM, Invitrogen, Carlsbad, CA, USA) and were frozen at passage 1 to 
serve as a master cell bank. More specifically, BMMSC and AdMSC were grown in 10 cm2 non-coated 
plastic vessels (Corning, Corning, NY, USA) in a 37 °C humidified incubator containing 5% CO2. When 
cells reached 80% confluence they were trypsinized (0.05% Trypsin/EDTA, Invitrogen) and were subse-
quently re-seeded at a density of 4,000 cells per cm2 in alternative media formulations. The remainder of 
the cells were frozen in 90%FBS (Hyclone, Bonn, Germany) and 10% dimethyl sulfoxide (DMSO, Sigma, 
Aldrich, St Louis, MO, USA).
Alternative media formulations consisted of DMEM supplemented with 10%HPL (BMMSC-
10%HPL, and AdMSC-10%HPL) and a commercially available serum-free/xeno-free culture medium 
(BMMSC-SFM/XF, AdMSC-SFM/XF) (StemPro® MSC SFM XenoFree termed SFM/XF, Invitrogen). 
HPL-supplemented medium contained heparin (2 IU/mL, Sigma), 1% penicillin/streptomycin (Gibco, 
Garlsbad, CA, USA), and 2 mM Glutamax (Gibco). SFM/XF culture medium was also supplemented with 
Glutamax (2 mM) according to manufacturer’s instructions. BMMSC-SFM/XF and AdMSC-SFM/XF 
were grown on CELLstart™ xeno-free substrate (Invitrogen) according to manufacturer’s instructions. All 
experiments were performed in comparison to BMMSC and AdMSC expanded in basal DMEM-medium 
supplemented with 10%FBS and 1% penicillin/streptomycin (BMMSC-10%FBS, AdMSC-10%FBS).
MSC priming. To generate IFN-γ pre-stimulated (primed) BMMSC and AdMSC, cells were seeded at 
the same density in all media formulations supplemented with 50 ng/mL of recombinant human IFN-γ 
(Sigma). IFN-γ treatment lasted three days as previously described14. All experiments were performed 
in comparison to vehicle- (1× phosphate buffer solution, PBS, supplemented with 0.1% bovine serum 
albumin, BSA) treated cells.
MSC cell size analysis. Cell size (area) of all MSC expanded in various media formulations was 
measured by a blinded investigator using Image J. All images were taken using an EVOS XL Core 
Cell Imaging System under 20× magnification objective. The cell size of the following number of cells 
was counted from each experimental condition: BMMSC-10%FBS (Vehicle; n = 57, IFN-γ ; n = 42), 
BMMSC-SFM/XF (Vehicle; n = 65, IFN-γ ; n = 39), BMMSC-10%HPL (Vehicle; n = 51, IFN-γ ; n = 50), 
www.nature.com/scientificreports/
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AdMSC-10%FBS (Vehicle; n = 60, IFN-γ ; n = 50), AdMSC-SFM/XF (Vehicle; n = 60, IFN-γ ; n = 83), 
and AdMSC-10%HPL (Vehicle; n = 65, IFN-γ ; n = 56). Images were obtained from multiple (5–6) opti-
cal fields of each cell culture plate.
Human platelet lysates (HPL) preparation. HPL was manufactured via three consecutive freeze and 
thaw cycles40 of platelet lysates obtained from the single donor apheresis platelet unit collected by Trima 
Accel cell separator (Trima, Terumo BCT) at the UCLA Blood and Platelet Center; these units failed to 
meet minimum platelet yield requirements and were not suitable for transfusion. Platelet rich plasma 
(PRP) prepared by cytapheresis was obtained from a clinical transfusion laboratory in UCLA. All sam-
ples were tested negative for common serology prior to usage. To avoid platelet clotting, all samples 
were supplemented with anti-coagulant (Heparin). PRP derived from five blood donors were combined 
by sterile connection to obtain a single homogenous product. The PRP used in the following studies 
was prepared from separate donors of blood group O. Subsequently, PRP was aliquoted in sterile tubes 
(50 mL) under aseptic conditions and aliquots underwent three cycles of freeze and thaw to promote 
efficient release of growth factors. To remove cellular debris, all processed samples were centrifuged at 
4,000 g at 4 °C for 15 minutes. Supernatant was transferred to new sterile tubes and frozen at − 80 °C.
MSC immunophenotypic analysis. Immunophenotypic analysis of expanded MSC was carried out 
using flow cytometry for the following markers: CD73, CD90, CD14, CD34, CD45, CD105, and MHCII 
(HLA-DR) (BD Biosciences)48. Samples were analyzed using a LSRII Flow Cytometer (BD Biosciences, 
San Jose, CA, USA) and the obtained data were analyzed with FlowJo software (FlowJo, version 7.6.1).
BrdU assays. BMMSC-10%FBS, BMMSC-SFM/XF, BMMSC-10%HPL, AdMSC-10%FBS, AdMSC-SFM/
XF, and AdMSC-10%HPL were seeded at a density of 2000 cells/cm2 and 24 hours later were treated with 
IFN-γ (50 ng/mL) for a period of 72 hours. At day 3, BrdU (10 μ M, BD Biosciences) was added in the 
culture medium and was allowed to incorporate into the DNA of the cells for three hours prior to flow 
cytometric analysis.
CFSE assays. BMMSC and AdMSC were primed with IFN-γ (50 ng/mL) for a period of 3 days prior 
to their seeding into a 96-well plate. One day after IFN-γ priming, human peripheral blood mono-
nuclear cells (PBMC), isolated from a single healthy donor, were stimulated with CD3+/CD28+ beads 
(Invitrogen) for a period of 3 days. CD3+/CD28+ -stimulated PBMC were pre-loaded with carboxyflu-
orescein succinimidyl ester (CFSE, Invitrogen) fluorescent dye and were cultured with primed BMMSC 
and AdMSC in various PBMC/MSC cell number ratios. CFSE is commonly used to monitor lymphocyte 
proliferation due to its progressive equal sharing within daughter cells following each cell division. CFSE 
fluorescence was assessed 96 hours following co-culture of MSC and PBMC via flow cytometric analysis.
Immunoblot analysis. BMMSC and AdMSC were washed with ice-cold PBS and incubated with assay 
buffer containing dithiothreitol (DTT) and protease inhibitors phenylmethylsulfonyl fluoride and sodium 
orthovanadate. The insoluble debris was removed by centrifugation (14,000 rpm, 5 min, and 4 °C) and 
supernatants were analyzed by immunoblot analysis. Equal amount of cell lysates (20–30 μ g) were loaded 
and transferred to a nitrocellulose membrane. The membrane was blocked with 1X Tris-Buffered Saline 
(TBS) containing 0.1% Tween-20 and 10% milk. The membranes were incubated with primary antibodies 
against IDO-1 and Tubulin-α (Cell Signaling, Boston, MA, USA) overnight at 4 °C under constant shak-
ing. Appropriate secondary pexodisase antibodies (goat-anti-rabbit IgG and goat-anti-mouse IgG, Sigma) 
were applied for 2 hours at ambient temperature. Membranes were washed with 1X TBS-T containing 
0.1% Tween-20. Enhanced chemiluminescence (ECL) was applied for the detection of horseradish per-
oxidase (HRP) activity from protein probes.
MSC differentiation assays. MSCs were seeded in 12-well culture plates at a density of 2500 cells/cm2 
and expanded until cells reached 80–90% confluency. For osteogenic and adipogenic differentiation 
and immuno-staining experiments, cells were stimulated for 14 days in differentiation media (GIBCO) 
according to manufacturer’s instructions. In the experiments intended for quantification of the differ-
entiation potential, MSC were cultured in differentiation media for 7 days. Osteogenic and adipogenic 
differentiation were assessed by staining for alkaline phosphatase (Fast Blue, Sigma) and for the pres-
ence of lipid droplets (Oil red O, Sigma)14. Quantitative real time polymerase chain reaction (qRT-PCR) 
was utilized for quantification of osteogenic and adipogenic differentiation efficacy in the various alter-
native media formulations. To quantify the effect of alternative media on the adipogenic and osteo-
genic differentiation, the expression of adiponectin, PPAR-γ , and alkanine phosphatase was assessed 
using the following sets of primers: PPAR-γ ; Forward: GAGCCCAAGTTTGAGTTTGC, Reverse: 
TCAATGGGCTTCACATTCAG, Adiponectin; Forward: CCTGGTGAGAAGGGTGAGAA, Reverse: 
CTCCTTTCCTGCCTTGGATT, Alkaline phosphatase: Forward: GACATCGCCTACCAGCTCAT, 
Reverse: TGGCTTTCTCGTCACTCTCA.
www.nature.com/scientificreports/
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Statistical Analysis. Statistical differences between groups were evaluated using one way Anova analysis 
and Student’s unpaired t-test, using GraphPad Prism (Version 5.03). All data are presented as mean ± SE. 
A p-value ≤ 0.05 was considered statistically significant.
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